Bioventus Inc.

BVS Nasdaq SEC CIK 1665988
Follow Bioventus Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $142.4M +2.7% vs same quarter last year
Net income $6M +89.8% vs same quarter last year
EPS, diluted $0.08 +60% vs same quarter last year
Operating cash flow $20.7M −31.4% vs same quarter last year
Revenue by quarter
$153.6M
$123.9M
$147.7M
$138.7M
$157.9M
$132.1M
$153.2M
$142.4M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income7 fiscal years
  • Revenue
  • Net income
−$200M$0$200M$400M$600MFY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$568.1M$22.7M
FY24$573.3M−$36.1M
FY23$512.3M−$156.2M
FY22$512.1M−$158.7M
FY21$430.9M-
FY20$321.2M$16.4M
FY19$340.1M$6.9M
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−50%0%50%100%FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearGross marginOperating marginNet margin
FY2568.3%9.5%4%
FY2467.7%−2.7%−6.3%
FY2364.1%−16%−30.5%
FY2264.6%−32.7%−31%
FY2170.3%2.8%-
FY2072.7%6.6%5.1%
FY1973.3%9.2%2%
Free cash flowOperating cash flow minus capital expenditure
−$25M$0$25M$50M$75MFY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25$72.1M
FY24$37.8M
FY23$8M
FY22−$15M
FY21$9.5M
FY20$55.2M
FY19$38.4M
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Bioventus
  • Healthcare median
−100%−75%−50%−25%0%25%FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearBioventusHealthcare median
FY254%−30.6%
FY24−6.3%−47%
FY23−30.5%−58%
FY22−31%−80.4%
FY21-−71.8%
FY205.1%−62.2%
FY192%−46.2%